© 2002 by Oxford University Press
Journal of the National Cancer Institute, Vol. 94, No. 7, 522-528,
April 3, 2002
© 2002 Oxford University Press
ARTICLE |
Activation of Cancer-Specific Gene Expression by the Survivin Promoter
Affiliations of authors: R. Bao, D. C. Connolly, J. K. Weinstein, D. A. Pisarcik, T. C. Hamilton, (Ovarian Cancer Program), M. Murphy (Department of Pharmacology), Fox Chase Cancer Center, Philadelphia, PA; J. Green, Laboratory of Cell Regulation and Carcinogenesis, National Cancer Institute, Bethesda, MD.
Correspondence to: Thomas C. Hamilton, Ph.D., Ovarian Cancer Program, Fox Chase Cancer Center, 7701 Burholme Ave., Philadelphia, PA 19111 (tc_hamilton{at}fccc.edu).
Background: Survivin, a member of the IAP (inhibitor of apoptosis) gene family, appears to be overexpressed in common cancers but not in corresponding normal adult tissues. To investigate whether the survivin promoter controls cancer cell–specific gene expression, we determined whether the survivin gene promoter could regulate reporter gene expression in cancer cell lines and xenografts. Methods: Survivin protein levels were determined in human and murine cancer cell lines and in normal tissues of adult C57BL/6 mice by Western blot analysis. A reporter construct in which a portion of the survivin gene promoter was used to drive transcription of a human secreted alkaline phosphatase (SEAP) gene was transiently transfected into cancer cells, and promoter activity was extrapolated from SEAP activity. A2780 human ovarian cancer cells were transfected with this construct, and stable transfectants were injected into the intrabursal ovarian space of immunodeficient mice. Tumor growth was monitored, and plasma SEAP levels were used as a measure of survivin promoter activity in vivo. Results: Survivin protein was detected in all cancer cell lines examined but not in most normal adult mouse tissues. After transfection, the survivin promoter was more active in all cancer cell lines than in normal ovarian surface epithelial cells or mouse 3T3 cells. After 0.8 x 106 stable transfectant cells were injected into the intrabursal cavity of mouse ovaries, plasma SEAP activity was detected within 24 hours, and the activity increased with time and tumor growth. Conclusion: Transfection experiments indicate that survivin protein expression in cancer tissue appears to be regulated, at least in part, transcriptionally. Thus, the survivin promoter may be useful in controlling gene expression in cancer cells.
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  C. N. Landen Jr, M. J. Birrer, and A. K. Sood Early Events in the Pathogenesis of Epithelial Ovarian Cancer J. Clin. Oncol., February 20, 2008; 26(6): 995 - 1005. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H. Caldas, F. O. Jaynes, M. W. Boyer, S. Hammond, and R. A. Altura Survivin and Granzyme B-induced apoptosis, a novel anticancer therapy. Mol. Cancer Ther., March 1, 2006; 5(3): 693 - 703. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. Kamizono, S. Nagano, Y. Murofushi, S. Komiya, H. Fujiwara, T. Matsuishi, and K.-i. Kosai Survivin-Responsive Conditionally Replicating Adenovirus Exhibits Cancer-Specific and Efficient Viral Replication Cancer Res., June 15, 2005; 65(12): 5284 - 5291. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. J. Reichenberger, R. D. Coletta, A. P. Schulte, M. Varella-Garcia, and H. L. Ford Gene Amplification Is a Mechanism of Six1 Overexpression in Breast Cancer Cancer Res., April 1, 2005; 65(7): 2668 - 2675. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. N. Span, F. C.G.J. Sweep, E. T.G. Wiegerinck, V. C.G. Tjan-Heijnen, P. Manders, L. V.A.M. Beex, and J. B. de Kok Survivin Is an Independent Prognostic Marker for Risk Stratification of Breast Cancer Patients Clin. Chem., November 1, 2004; 50(11): 1986 - 1993. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
B. Lu, Y. Mu, C. Cao, F. Zeng, S. Schneider, J. Tan, J. Price, J. Chen, M. Freeman, and D. E. Hallahan Survivin As a Therapeutic Target for Radiation Sensitization in Lung Cancer Cancer Res., April 15, 2004; 64(8): 2840 - 2845. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. Tanaka, K. Uzawa, T. Shibahara, H. Yokoe, H. Noma, and H. Tanzawa Expression of an Inhibitor of Apoptosis, Survivin, in Oral Carcinogenesis J. Dent. Res., August 1, 2003; 82(8): 607 - 611. [Abstract] [Full Text]
|
|
|
|
 |
|
 N. S. Williams, R. B. Gaynor, S. Scoggin, U. Verma, T. Gokaslan, C. Simmang, J. Fleming, D. Tavana, E. Frenkel, and C. Becerra Identification and Validation of Genes Involved in the Pathogenesis of Colorectal Cancer Using cDNA Microarrays and RNA Interference Clin. Cancer Res., March 1, 2003; 9(3): 931 - 946. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Kappler, M. Kotzsch, F. Bartel, S. Fussel, C. Lautenschlager, U. Schmidt, P. Wurl, M. Bache, H. Schmidt, H. Taubert, et al. Elevated Expression Level of Survivin Protein in Soft-Tissue Sarcomas Is a Strong Independent Predictor of Survival Clin. Cancer Res., March 1, 2003; 9(3): 1098 - 1104. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
N. R. Wall, D. S. O'Connor, J. Plescia, Y. Pommier, and D. C. Altieri Suppression of Survivin Phosphorylation on Thr34 by Flavopiridol Enhances Tumor Cell Apoptosis Cancer Res., January 1, 2003; 63(1): 230 - 235. [Abstract] [Full Text] [PDF]
|
|